Top entities: ADMA Biologics, Pomerantz LLP, Culper Research, Cantor Fitzgerald, Nasdaq-100.

What category does this event fall under?

Regulatory — classified as securities fraud investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 28, 2026. Coverage continues to evolve.

Regulatory securities fraud investigation

ADMA Biologics Securities Fraud Investigation

Q: When did this event occur?

First reported May 19, 2026; last updated May 28, 2026.

Q: What is the market impact?

Direct. The market is negatively impacted by the allegations of securities fraud against ADMA Biologics, leading to a significant decline in its stock price.

Q: What were the key actions taken?

Culper Research published report ADMA Biologics · Pomerantz LLP investigated claims ADMA Biologics · Cantor Fitzgerald downgraded ADMA Biologics

Analysis based on 7 articles · First reported May 19, 2026 · Last updated May 28, 2026

Sentiment

-70

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the allegations of securities fraud against ADMA Biologics, leading to a significant decline in its stock price. This event also highlights the role of short-sellers like Culper Research and analysts like Cantor Fitzgerald in influencing market sentiment and stock valuations.

biotechnology legal services

Event Summary

Pomerantz LLP is investigating ADMA Biologics, Inc. for alleged securities fraud and unlawful business practices. This investigation follows a short report published by Culper Research on March 24, 2026, which accused ADMA Biologics of channel stuffing and misrepresenting its growth, causing its stock price to fall by 16.63%. Subsequently, Cantor Fitzgerald downgraded ADMA Biologics on March 26, 2026, due to the company's unsatisfactory response to the report, leading to another 13.91% drop in stock price. On May 6, 2026, ADMA Biologics further impacted its stock by withdrawing its long-term financial guidance, resulting in a 15.97% decline. These events have collectively led to a significant decrease in ADMA Biologics's market value and raised concerns among investors.

Key Actions

95 Culper Research published report ADMA Biologics

90 Pomerantz LLP investigated claims ADMA Biologics

85 Cantor Fitzgerald downgraded ADMA Biologics

80 ADMA Biologics withdrew financial guidance

Entities Involved

stock

ADMA Biologics

ADMA Biologics is under investigation for alleged securities fraud and unlawful business practices, leading to significant drops in its stock price and the withdrawal of its long-term financial guidance.

Importance 100 Sentiment -80

priv

Pomerantz LLP

Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. for alleged securities fraud, potentially leading to a class action lawsuit.

Importance 80 Sentiment 50

priv

Culper Research

Culper Research published a short report alleging ADMA Biologics's reported growth is a fiction, which triggered a significant drop in ADMA Biologics's stock price.

Importance 70 Sentiment 60

priv

Cantor Fitzgerald

Cantor Fitzgerald downgraded ADMA Biologics, citing disappointment with the company's response to the Culper Research report, further contributing to the decline in ADMA Biologics's stock price.

Importance 60 Sentiment 20

index

Nasdaq-100

Nasdaq-100 is the exchange where ADMA Biologics's stock is traded, and its price fluctuations are reported on this exchange.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard